Phase 1 - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Phase 1

DARE, NASDAQ

#Phase 1 #Positive Clinical Trial Results

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

January 26, 2023
08:00

EST

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) — Daré Bioscience,

No Comments

ACIU, NASDAQ

#Alzheimer #Phase 1 #Trending News

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

January 26, 2023
07:00

EST

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort ACI-24.060 was generally well tolerated with no safety concerns observed With these findings, dosing in the second,

No Comments

NBIO, OTC

#Cancer #Phase 1

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

January 25, 2023
08:01

EST

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (Nascent Biotech, Nascent, or the Company), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety

No Comments

NBIO, OTC

#Cancer #Phase 1

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

January 25, 2023
08:00

EST

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety

No Comments

NASDAQ, PGEN

#Expansion #Featured #Phase 1 #Positive Clinical Trial Results #Trending News

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

January 24, 2023
16:01

EST

– Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – – Clinical data show strong response in RRP patients with 50% of patients in Complete Response, requiring no post-treatment surgeries, following PRGN-2012 treatment at Dose Level 2; All

No Comments

BGAVF, OTC

#Drilling Update #Phase 1

Bravada Files Technical Report for the Wind Mountain Au/Ag Project, Nevada, Including Phase I PEA Results of 38% IRR and US$46.1 Million After-Tax [email protected]%

January 24, 2023
13:33

EST

Vancouver, British Columbia–(Newsfile Corp. – January 24, 2023) – Bravada Gold Corporation (TSXV: BVA) (OTCQB: BGAVF) (FSE: BRTN) (the “Company” or “Bravada”) reports today that it has filed a technical report (the “Report”) prepared in accordance with Canadian Securities Administrators’ National Instrument 43-101 (“NI 43-101”). The Report may be

No Comments

ALLO, NASDAQ

#Cancer #New Clinical Trial Data #Phase 1 #Trending News

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

January 24, 2023
08:30

EST

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for

No Comments

NASDAQ, VTGN

#NASA #New Clinical Trial Data #Phase 1 #Trending News

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

January 24, 2023
08:30

EST

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the first cohort of healthy volunteers has been dosed in its U.S. Phase 1 clinical trial

No Comments

NASDAQ, RAIN

#Cancer #New Clinical Trial Data #Phase 1 #Trending News

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

January 23, 2023
08:00

EST

– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA trial – NEWARK, Calif., Jan. 23, 2023

No Comments

MRTX, NASDAQ

#Cancer #FDA Clearance #Phase 1 #Trending News

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

January 19, 2023
17:00

EST

IND demonstrates Mirati’s leadership in KRAS, representing the Company’s third KRAS or KRAS-signaling program to enter clinical development SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a

No Comments

< Page1 Page2 Page3 … Page67 >

Trending News

Helbiz Provides Transparency on Filed Proxy Statement

01/27/2023

CNEY Announces Proposed Underwritten Public Offering of Securities

01/27/2023

CNEY Reports Its Audited Financial Results for Fiscal Year 2022

01/27/2023

Hannon Armstrong Announces 2022 Dividend Income Tax Treatment

01/27/2023

DecisionPoint Systems Launches MobileConductor Express

01/27/2023

Most read news

STEER Announces a Proposed Transaction for an $18 Million Direct Investment Involving its Digital Restaurant Supply Business (B2B Marketplace)

01/23/2023

Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress

01/23/2023

Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics

01/26/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account